Jason Westin

71PUBLICATIONS
296CO-AUTHORS
ChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (71)

|Jul 06, 2026
The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

|Jul 02, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

|Jun 24, 2026
A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

|Mar 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Nicolas Gower, Pierre Feugier, Jason R Westin

|Nov 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Richard T Maziarz, Michael R Bishop, Constantine S Tam

|Nov 13, 2025
Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.

Caron A Jacobson, Jason R Westin, David B Miklos

Pageof 12

Frequent Collaborators

20 joint publications

Sattva S Neelapu

14 joint publications

Sairah Ahmed

13 joint publications

Raphael Steiner

13 joint publications

Maria Rodriguez